Abstract: OBJECTIVE To evaluate the incidences of adverse reactions in the clinical use of dopamine. METHODS Relevant studies available before June 2018 were identified by searching CNKI, WanFang, VIP, CBM, PubMed, EMBASE, the Cochrane Library and ClinicalTrials.gov using the following keywords:dopamine, safety, adverse reactions, adverse events, side effects and adverse effects. The incidences of adverse reactions in the included literatures were calculated by using meta-analysis. RESULTS A total of 68 studies (78 groups) were included. The incidence of total adverse reactions in the clinical use of dopamine was 17.2% (95% CI:9.2%-25.1%), and the highest incidence was tissue damage or gangrene (19.5%, 95% CI:12.6%-26.4%), followed by arrhythmia (15.7%, 95% CI:7.4%-24.0%). The incidence of severe adverse reactions was 7.3% (95% CI:3.6%-11.0%). The incidences of total adverse reactions in adults and children were 7.0% and 15.1%, respectively. The most common adverse reaction in adults was arrhythmia (15.7%, 95% CI:7.4%-24.0%) and the most common adverse reaction in children was tissue damage or gangrene (25.3%, 95% CI:13.0%-37.6%). The incidence of total adverse reactions was higher in the high dose group (>10 μg·kg^-1·min^-1), which was 16.0% (95% CI:4.8%-27.3%). Among the different dosage forms, the incidence of adverse reactions of dopamine powder injection was 2.9% (95% CI:0.6%-5.1%), which was lower than that of dopamine water injection (16.9%, 95% CI:7.8%-26.0%). CONCLUSION There are many types of adverse reactions in clinical use of dopamine and the incidences of adverse reactions are high. Dopamine should be closely monitored in clinical use.